Atreca Inc BCEL

Alternate Symbol(s): COLUF

Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.

PINL:BCEL - Post by User

Atreca Inc

Bullboard Posts

Comment by sweatmanon Jun 18, 2013 4:17pm

212 Views

Post# 21539068

RE: RE: RE: This is NUTS!!!

The Brazilian government is not 'mulling' over an increase in royalty payments. That will be a given. What is a mystery is how much will the government grab. And although Brazil and its currency have challenges right now, it would be unwise to grab too much...and I think the government understands that. I have no doubts the company and the financial geniuses who thought a double-raise at these prices was a good idea have a handle on what the government will do. One would think, anyway. I figured from the get-go that $1.25 to $1.40 was a good entry level price and have not changed my mind.

Bullboard Posts

One of the best stocks for a silver rebound play